180 Life Sciences Corp SEC Filings

180 Life Sciences Corp. (ATNF) – Form 4 overview

Director Ryan Lewis Smith reported changes in beneficial ownership effective 12 July 2025. The filing discloses:

• Common shares held: 167,181 shares, shown as direct ownership after the reported transactions.
• Stock options: 255,000 non-qualified options with a $0.929 exercise price and a 17 June 2035 expiration.
• Key event: The Board, following Compensation Committee recommendation, accelerated vesting of 100 % of these options on 12 July 2025. Originally, one-half was to vest on 17 Dec 2025 and the balance on 17 Jun 2026.
• Contingencies: (i) No option may be exercised until shareholders approve the 2025 Option Incentive Plan; (ii) the options will be cancelled if such approval is not obtained.

No purchase or sale of common stock occurred; the filing strictly reflects a change in derivative security vesting status. Potential dilution arises if the options become exercisable and are ultimately exercised, but this remains conditional on a future shareholder vote.

180 Life Sciences Corp. (ATNF) – Form 4 overview

Director Ryan Lewis Smith reported changes in beneficial ownership effective 12 July 2025. The filing discloses:

• Common shares held: 167,181 shares, shown as direct ownership after the reported transactions.
• Stock options: 255,000 non-qualified options with a $0.929 exercise price and a 17 June 2035 expiration.
• Key event: The Board, following Compensation Committee recommendation, accelerated vesting of 100 % of these options on 12 July 2025. Originally, one-half was to vest on 17 Dec 2025 and the balance on 17 Jun 2026.
• Contingencies: (i) No option may be exercised until shareholders approve the 2025 Option Incentive Plan; (ii) the options will be cancelled if such approval is not obtained.

No purchase or sale of common stock occurred; the filing strictly reflects a change in derivative security vesting status. Potential dilution arises if the options become exercisable and are ultimately exercised, but this remains conditional on a future shareholder vote.

180 Life Sciences Corp. (ATNF) – Form 4 filing, 14 Jul 2025

Chief Accounting Officer Eric R. Van Lent reported changes in his beneficial ownership. The filing shows he now holds 8,174 common shares directly and a non-qualified stock option for 25,000 shares with a $0.929 exercise price.

The option was originally scheduled to vest 50 % on 17 Dec 2025 and 50 % on 17 Jun 2026. On 12 Jul 2025, the Board accelerated vesting of the entire award, making all 25,000 options fully vested as of that date. Key contingency: the options cannot be exercised until shareholders approve the company’s 2025 Option Incentive Plan; if approval is not obtained, the options will be cancelled.

No open-market purchases or sales of common stock are reported, and ownership remains direct. The disclosure signals the company’s intent to retain a key finance executive but leaves potential dilution dependent on upcoming shareholder consent.

The Form 4 filing discloses an internal re-registration of 160,000 common shares of 180 Life Sciences Corp. (ATNF) by CEO, Director and 10% owner Blair Jordan. The shares were moved from Jordan’s direct ownership to his wholly-owned entity, Blair Jordan Strategy and Finance Consulting Inc., under Transaction Code “J” (transfer) for tax-planning purposes; footnote 1 confirms no change in beneficial ownership.

After the transfer, Jordan’s indirect holdings through the entity total 327,576 shares. In addition, he is deemed to have beneficial ownership (via voting proxies, not economic interest) over 1.56 million shares held by other parties—43,166 from Dr. Woody, 200,000 from Dr. Krauss and 1,318,000 from Elray Resources, all subject to time-limited voting agreements.

The filing also notes an earlier grant of 410,000 non-qualified stock options at an exercise price of $0.929. On 12 Jul 2025 the Board accelerated 100% vesting, but the options remain unexercisable until shareholders approve the company’s 2025 Incentive Plan; they will be cancelled if approval is not obtained.

No cash consideration, change in control or open-market buying/selling occurred. The disclosure is primarily administrative, signalling continued insider control and highlighting a potential future dilution event tied to plan approval.

180 Life Sciences Corp. (NASDAQ: ATNF/ATNFW) filed an 8-K on 11-12 July 2025 disclosing compensation-related actions approved by its Board of Directors.

• Accelerated vesting – executives: The Board accelerated in-full vesting of (i) 435,000 stock options (exercise price $0.9290; 10-year term) and (ii) 175,750 restricted shares previously granted on 17 June 2025 to CEO Blair Jordan and CAO Eric Van Lent.
• Accelerated vesting – non-executive directors: Vesting of 530,000 options (same $0.9290 exercise price) and 214,579 restricted shares granted on 17 June 2025 to three independent directors was likewise accelerated.
• Shareholder approval still required: Under Nasdaq rules and the company’s 2025 Option Incentive Plan, none of the accelerated options may be exercised until shareholders approve the 2025 Plan. If approval is not obtained within one year of adoption, all options issued under the plan will be cancelled.
• Consulting agreement amendment: On 12 July 2025, the company, Eric Van Lent and EVL Consulting, LLC extended Mr. Van Lent’s Executive Consulting Agreement through 31 Dec 2025 and increased the early-termination fee from $10,000 to $25,000.
• No financial or operational metrics were reported.

The filing contains updated exhibits for the 2025 Option Incentive Plan, related award agreements and the amended consulting agreement.

Granite Construction Incorporated (NYSE:GVA) has filed an 8-K announcing the retirement of Executive Vice President & Chief Operating Officer James Radich effective 4 July 2025. The filing focuses on the departure terms and transition arrangements.

Severance Agreement:

• Accrued but unpaid salary through 4 July 2025 will be paid promptly.
• Eligibility to receive 2025 Annual Incentive Plan payout based on actual performance.
• Pro-rated cash settlement of outstanding long-term incentive awards through the end of each performance period, including accrued and unused vacation.
• Lump-sum cash payment equal to 18 months of COBRA healthcare coverage for the executive and eligible dependents.
• Customary non-solicitation, non-disparagement, cooperation and release provisions.
• One-time retirement gift valued at approximately $3,000.

Consulting Agreement:

• Radich may provide consulting services from the separation date through 31 October 2025, extendable by mutual consent.
• Hourly compensation set at $250.
• Scope includes management transition support, project and construction oversight, claim review and other business matters.
• Agreement contains standard confidentiality and non-compete clauses.

The company attached the Severance Agreement (Ex. 10.1) and Consulting Agreement (Ex. 10.2) for full detail. No successor COO has been named in this filing. The arrangement suggests an orderly transition but removes an experienced operator from day-to-day duties. Financial impact appears limited to salary accruals, incentive payouts and consulting fees, which were not quantified beyond the hourly rate.

MongoDB, Inc. (MDB) – Form 4 insider filing dated 07/02/2025

Board director Roelof Botha reported the receipt of additional Class A common shares on 06/30/2025 under the company’s non-employee director compensation program.

• Restricted Stock Units (RSUs): 1,130 units granted at $0 cost. The award vests in full on the earlier of (i) 06/30/2026 or (ii) the 2026 annual meeting, conditional on continued service.
• Stock-in-Lieu of Cash Fees: 246 fully-vested shares issued at $0 cost, calculated using the 30-day VWAP preceding the grant date.

Post-transaction ownership

• Direct holdings: 3,067 Class A shares (previously 1,691).
• Indirect holdings: 217,513 Class A shares held via estate-planning vehicles.

No shares were sold or disposed of, indicating a net increase of 1,376 shares. Because the grants are part of routine board compensation and represent a small fraction of Botha’s existing indirect holdings and MDB’s ~70 million share float, the market impact is expected to be limited. Nevertheless, continued share accumulation by a long-serving director may be viewed as a sign of alignment with shareholder interests.

Lexeo Therapeutics (Nasdaq: LXEO) has filed a Rule 424(b)(3) prospectus to register up to 41,630,514 common shares for resale by investors that participated in a May 28 2025 private placement. The registered shares comprise 20.8 million outstanding shares plus 20.8 million shares underlying pre-funded ($0.0001 strike, no expiry) and common warrants ($2.82 strike, expiring May 28 2029>). The placement raised ≈$80 million at $2.8825 per share/unit; warrant exercises could generate an additional $39.1 million in cash. Lexeo will receive no proceeds from secondary sales but will cover registration expenses.

The capital, together with a recently redeployed $20 million from pre-clinical programs and a $75 million unused ATM facility, is expected to fund operations into 2028 and accelerate initiation of a registrational study for lead candidate LX2006 by early 2026.

Pipeline highlights

• LX2006 (AAVrh10 gene therapy for Friedreich ataxia cardiomyopathy) – Phase 1/2 interim data (Apr 2025, n=16) showed dose-responsive increases in frataxin protein and improvements in cardiac biomarkers (LV mass index, lateral wall thickness, hs-troponin I) and functional measures (mFARS, KCCQ-12). FDA has agreed to an accelerated-approval pathway using LV mass index and frataxin expression as co-primary endpoints.
• LX2020 (PKP2 arrhythmogenic cardiomyopathy) – Phase 1/2 HEROIC-PKP2 (n=6) demonstrated 71-115 % PKP2 protein increases in two biopsied patients and a 67 % PVC reduction in the first six-month follow-up. Interim efficacy read-out is expected 2H-2025.

The company remains an emerging growth and smaller reporting company, permitting scaled disclosure under U.S. securities laws. On June 30 2025 LXEO closed at $4.02.